Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients.

doi:10.1111/j.1600-0773.1996.tb00211.x

Back to search

Article

Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients.

Pharmacology & toxicology - 1 Apr 1996

Risch A, Smelt V, Lane D, Stanley L, van der Slot W, Ward A, Sim E

Abstract excerpt

Sulphamethoxazole, a substrate of human arylamine N-acetyltransferase, is used in the treatment of cystic fibrosis patients, who metabolise the drug rapidly. Increased metabolic clearance of sulphamethoxazole has been suggested to account for this rapid metabolism. Arylamine N-acetyltransferase t...

Topics

Adolescent
Adult
Alleles
Anti-Infective Agents
Arylamine N-Acetyltransferase
Cystic Fibrosis
Erythrocytes
Humans
Isoenzymes
Mutation
Polymerase Chain Reaction
Polymorphism, Restriction Fragment Length
Sulfamethoxazole

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.